Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure
Status: | Recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/6/2019 |
Start Date: | April 7, 2014 |
End Date: | May 2020 |
Contact: | Makinzee Kazeck |
Email: | kazeck.makinzee@mayo.edu |
Phone: | 507-255-2200 |
Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID-HF)
Determine the impact of restoring normal heart rate response during exercise and daily
activity in patients with heart failure and a preserved ejection fraction (HFpEF) and
chronotropic incompetence (CI).
activity in patients with heart failure and a preserved ejection fraction (HFpEF) and
chronotropic incompetence (CI).
Inclusion Criteria
1. Age >18 years and able to provide informed consent to enroll in the trial, or consent
through a legal guardian or power of attorney.
2. Previous clinical diagnosis of HF with current NYHA Class II-III symptoms
3. At least one of the following: Hospitalization for decompensated HF, Acute treatment
for HF with intravenous loop diuretic or hemofiltration, Chronic treatment with a loop
diuretic for control of HF symptoms + left atrial enlargement on echocardiography
4. Left ventricular EF ≥50% within 12 months with clinical stability
5. Stable cardiac medical therapy for ≥30 days
6. Sinus rhythm
7. Chronotropic incompetence on recent (within 6 months) clinical or screening exercise
test, defined as heart rate reserve (HRR) <0.80
8. Meet both screening criteria on clinically-performed cardiopulmonary exercise testing
within 12 months. Peak VO2 ≤60% age/sex-adjusted normal value + peak respiratory
exchange ratio (RER) ≥1.05 One of the following: NT-proBNP ≥400 pg/mL or NT-proBNP
<400 pg/mL, with rest PCWP >20 mmHg and/or >25 mmHg with exercise
Exclusion Criteria
1. Inability to exercise, or non-cardiac condition that precludes exercise testing
2. Any contraindication to a pacemaker system
3. Non-cardiac condition limiting life expectancy to less than one year
4. Significant left sided structural valve disease (>mild stenosis, >moderate
regurgitation)
5. Hypertrophic cardiomyopathy
6. Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)
7. Pericardial disease
8. Non-group 2 pulmonary arterial hypertension
9. Chronic stable exertional angina
10. Acute coronary syndrome or revascularization within 60 days
11. Other clinically important causes of dyspnea
12. Atrial fibrillation
13. PR interval >210 msec
14. Resting heart rate (HR) > 100 bpm
15. A history of reduced ejection fraction (EF<50%)
16. Advanced chronic kidney disease (GFR < 20 ml/min/1.73m2 by modified MDRD equation)
17. Women of child bearing potential without negative pregnancy test and effective
contraception
18. Severe anemia (Hemoglobin <10 g/dL)
19. Severe hepatic disease
20. Complex congenital heart disease
21. Listed for cardiac transplantation
22. Other class I indications for pacing
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Barry Borlaug
Phone: 507-255-2200
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials